ADVANZ PHARMA CORP. LIMITED

Inactive Instrument

Other languages ADVANZ PHARMA Corp. Limited

Equities

CXRXF

JE00BJVH6L55

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADVANZ PHARMA Corp. Limited completed the acquisition of Global rights of Tostran from Kyowa Kirin Co., Ltd..	23-10-17
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe	23-05-24
Applied Therapeutics, Inc. Announces Partnership with Advanz Pharma for Commercialization of AT-007 in Europe	23-01-04
ADVANZ PHARMA Corp. Limited acquired Portfolio Of Generic Drugs Of Sanofi.	22-10-02
ADVANZ PHARMA Corp. Limited Limited Names Susanna El-Armale as Chief Corporate Development Officer	22-04-01
Steffen Wagner Assumes His Position as New Chief Executive Officer At ADVANZ PHARMA Corp. Limited	22-04-01
ADVANZ PHARMA Corp. Limited Announces Earnings Results for the First Quarter Ended March 31, 2021	21-05-14
Advanz Pharma Corp. Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-17
Advanz Pharma Corp. Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-06
ADVANZ PHARMA Provides Earnings Guidance for the Fourth Quarter of 2020	20-11-06
ADVANZ PHARMA : Earnings Flash (CXRXF) ADVANZ PHARMA Posts Q3 Revenue $128.7M	20-11-06
ADVANZ PHARMA Corp Receives Preliminary Approaches from Parties	20-10-26
Advanz Pharma Corp. Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12
ADVANZ PHARMA Corp. Limited Provides Earnings Guidance for the Third Quarter of 2020	20-08-12
Concordia International Corp. Provides Earnings Guidance for the Full Year of 2016	16-09-16
Concordia International Corp. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Report Impairment Loss for the Second Quarter of 2016; Revises Earnings Guidance for the Year 2016	16-08-12
Concordia Healthcare Corp. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Reaffirms Earnings Guidance for the Fiscal Year 2016	16-05-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer